Skip to main content
Back
Watch Compare

Galera Therapeutics, Inc.

Data quality: 83%
GRTX
OTC Manufacturing Chemicals
$0.09
▼ $0.00 (-0.12%)
6 months return
—
Momentum
Neutral
Free cash flow
-6.05 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROIC-50.31%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio8.20
Interest CoverageN/A

Valuation

PE (TTM)
0.02
Above sector avg (-1.49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -6.05 M
P/E of 0.02 — trading at a low valuation

Price History

Financial Trends

Analyst Price Target

No analyst coverage available

Earnings Surprises

EPS
Reported Estimate
Q42022 Q12023 Q22023 Q32023
Reported -$0.58 -$0.50 -$0.48 -$0.33
Estimate -$0.51 -$0.43 -$0.38 -$0.40
Surprise -14.81% -16.35% -26.88% +16.92%

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: N/A · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) 149.05 M
ROE N/A ROA 2697.72%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -6.05 M
ROIC -50.31% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 8.20
Debt / Equity N/A Current Ratio 8.20
Interest Coverage N/A Asset Turnover N/A
Working Capital 4.30 M Tangible Book Value -149.22 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: 0.02 · EV/EBITDA: N/A
P/E Ratio 0.02 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -195.51%
Market Cap 3.09 M Enterprise Value -1.38 M

Per Share

EPS: 0.64 · FCF/Share: -0.08
EPS (Diluted TTM) 0.64 Revenue / Share N/A
FCF / Share -0.08 OCF / Share -0.08
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: -4.06% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion -4.06%
SBC-Adj. FCF -6.92 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income 149.05 M -18.96 M -59.08 M -62.22 M -80.53 M
EPS (Diluted) 0.64 -0.34 — — —
Gross Profit — — — — —
Operating Income -2.54 M -20.16 M -49.26 M -51.23 M -73.37 M
EBITDA — — — — —
R&D Expenses 349,000.0 3.15 M 24.12 M 31.01 M 52.42 M
SG&A Expenses — — — — —
D&A 0.0 20,000.0 259,000.0 114,000.0 778,000.0
Interest Expense 0.0 0.0 11.41 M 11.57 M 7.19 M
Income Tax 0.0 -203,000.0 0.0 70,000.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7.20 M 10.10 M 26.14 M 44.04 M 83.31 M
Total Liabilities 645,000.0 153.77 M 157.33 M 153.22 M 141.32 M
Shareholders' Equity 3.97 M -148.04 M -131.19 M -109.18 M -58.00 M
Total Debt — — — — —
Cash & Equivalents 6.38 M 8.29 M 18.26 M 4.27 M 19.86 M
Current Assets 7.10 M 10.00 M 21.63 M 38.54 M 77.39 M
Current Liabilities 645,000.0 1.67 M 4.96 M 13.38 M 12.94 M

Peer Comparison

vs Manufacturing sector median (1605 peers)
Metric Stock Sector Median
P/E 0.0 -1.5
P/B — 1.6
ROE % — -54.7
Net Margin % — -41.5
Rev Growth 5Y % — 1.7
D/E — 0.3